Washington, DC — Today, the Supreme Court of the United States announced it will hear Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration next term. Earlier this year, Judge Matthew Kacsmaryk invalidated the FDA’s approval of mifepristone and the 5th Circuit Court of Appeals severely restricted access to mifepristone, but the Supreme Court stayed this decision. The case threatens safe and legal abortion access and would create chaos in the FDA drug approval process by allowing any judge to overrule the evidence-based and scientific approval of medications.
Watch Protect Our Care’s event with legal and public health experts discussing the dangers of this case here.
In response, Protect Our Care Chair Leslie Dach issued the following statement:
“This case threatens the entire U.S. drug approval process and puts the health of Americans at risk. The stakes couldn’t be higher for millions of patients across the nation. If the lower courts’ decisions are allowed to stand, any judge could overturn the FDA’s world-class drug approval process, ripping away access to safe, effective, and lifesaving drugs. It would create chaos in our drug approval process.”